A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Retaspimycin (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms RING
- Sponsors Infinity Pharmaceuticals
- 05 Oct 2021 This trial has been completed in France (End Date: 15 Apr 2009), according to European Clinical Trials Database record.
- 21 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 21 Apr 2012 Planned number of patients changed from 195 to 229 as reported by European Clinical Trials Database.